High dose of commercial products of kava (Piper methysticum) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats

Food and Chemical Toxicology

Volumn 46, Issue 12, 2008, Pages 3732-3738

  Yamazaki, Yuko ^a   Hashida, Hiroko ^a   Arita, Anna ^a   Hamaguchi, Keiko ^a   Shimura, Fumio ^a  

^a JUMONJI UNIVERSITY   (Japan)

Author keywords

Cytochrome P450 1A1; Hepatotoxicities; Kava; mRNA expression; Piper methysticum; Rat liver; Real time RT PCR

Indexed keywords

AFLATOXIN; BENZO[A]PYRENE; CYTOCHROME P450 1A1; ETHOXYRESORUFIN DEETHYLASE; ISOENZYME; KAVA; LACTONE DERIVATIVE; MESSENGER RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; GENE EXPRESSION; HEPATOMEGALY; IMMUNOREACTIVITY; LIVER WEIGHT; MALE; METABOLIC ACTIVATION; NONHUMAN; RAT; RISK ASSESSMENT;

ANIMALS; BLOTTING, WESTERN; BODY WEIGHT; CATALYSIS; CYTOCHROME P-450 CYP1A1; HEPATOMEGALY; KAVA; LIVER; MALE; ORGAN SIZE; RATS; RATS, SPRAGUE-DAWLEY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

PIPER METHYSTICUM; RATTUS;

EID: 55949103189     PISSN: 02786915     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.fct.2008.09.052     Document Type: Article

References (42)

1. Bilia A.R., Gallon S., and Vincieri F.F. Kava-kava and anxiety: growing knowledge about the efficacy and safety. Life Sci. 70 (2002) 2581-2597
2. Clayton N.P., Yoshizawa K., Kissling G.E., Burka L.T., Chan P.C., and Nyska A. Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. Exp. Toxicol. Pathol. 58 (2007) 223-236
3. Escher M., Desmeules J., Giostra E., and Mentha G. Hepatitis associated with Kava, a herbal remedy for anxiety. BMJ 322 (2001) 139
4. Garrett K.M., Basmadjian G., Khan I.A., Schaneberg B.T., and Seale T.W. Extracts of kava (Piper methysticum) induce acute anxiolytic-like behavioral changes in mice. Psychopharmacology (Berl.) 170 (2003) 33-41
5. Gounder R. Kava consumption and its health effects. Pac. Health Dialog 13 (2006) 131-135
6. Guengerich F.P. Microsomal enzymes involved in toxicology analysis and separation. In: Hayes A.W. (Ed). Principles and Methods of Toxicology (1982), Raven Press, New York 609-634
7. Gurley B.J., Gardner S.F., Hubbard M.A., Williams D.K., Gentry W.B., Khan I.A., and Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin. Pharmacol. Ther. 77 (2005) 415-426
8. Gurley B.J., Swain A., Hubbard M.A., Williams D.K., Barone G., Hartsfield F., Tong Y., Carrier D.J., Cheboyina S., and Battu S.K. Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: Effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea. Mol. Nutr. Food Res. (2008) Jan 23 [Epub ahead of print]
9. Herrman J.L., and Younes M. Background to the ADI/TDI/PTWI. Regul. Toxicol. Pharmacol. 30 (1999) S109-S113
10. Kennedy S.W., Lorenzen A., James C.A., and Collins B.T. Ethoxyresorufin O-deethylase and porphyrin analysis in chicken embryo hepatocyte cultures with a fluorescence multiwell plate reader. Anal. Biochem. 211 (1993) 102-112
11. Kenworthy K.E., Bloomer J.C., Clarke S.E., and Houston J.B. CYP3A4 drug interactions: correlation of 10 in vitro probe substrates. Br. J. Clin. Pharmacol. 48 (1999) 716-727
12. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227 (1970) 680-685
13. Lim S.T., Dragull K., Tang C.S., Bittenbender H.C., Efird J.T., and Nerurkar P.V. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. Toxicol. Sci. 97 (2007) 214-221
14. Liu Y.T., Hao H.P., Liu C.X., Wang G.J., and Xie H.G. Drugs as CYP3A probes, inducers, and inhibitors. Drug Metab. Rev. 39 (2007) 699-721
15. Luo G., Guenthner T., Gan L.S., and Humphreys W.G. CYP3A4 induction by xenobiotics: biochemistry, experimental methods and impact on drug discovery and development. Curr. Drug Metab. 5 (2004) 483-505
16. Ma Q., and Lu A.Y. CYP1A induction and human risk assessment: an evolving tale of in vitro and in vivo studies. Drug Metab. Dispos. 35 (2007) 1009-1016
17. Ma Y., Sachdeva K., Liu J., Ford M., Yang D., Khan I.A., Chichester C.O., and Yan B. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of CYP3A23. Drug Metab. Dispos. 32 (2004) 1317-1324
18. Malsch U., and Kieser M. Efficacy of kava-kava in the treatment of non-psychotic anxiety, following pretreatment with benzodiazepines. Psychopharmacology (Berl.) 157 (2001) 277-283
19. Mathews J.M., Etheridge A.S., and Black S.R. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. Drug Metab. Dispos. 30 (2002) 1153-1157
20. Mathews J.M., Etheridge A.S., Valentine J.L., Black S.R., Coleman D.P., Patel P., So J., and Burka L.T. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones in vivo and in vitro. Drug Metab. Dispos. 33 (2005) 1555-1563
21. Nebert D.W., Dalton T.P., Okey A.B., and Gonzalez F.J. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 279 (2004) 23847-23850
22. Norton S.A., and Ruze P. Kava dermopathy. J. Am. Acad. Dermatol. 31 (1994) 89-97
23. O'Sullivan H.M., and Lum K. The poisoning of 'awa: the non-traditional use of an ancient remedy. Pac. Health Dialog 11 (2004) 211-215
24. Pittler M.H., and Edzard E. Kava extract for treating anxiety. Cochrane Database Syst. Rev. 4 (2001) CD003383
25. Raucy J.L. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos. 31 (2003) 533-539
26. Rex A., Morgenstern E., and Fink H. Anxiolytic-like effects of kava-kava in the elevated plus maze test - a comparison with diazepam. Prog. Neuropsychopharmacol. Biol. Psychiatry 26 (2002) 855-860
27. Russmann S., Lauterburg B.H., Barguil Y., Choblet E., Cabalion P., Rentsch K., and Wenk M. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens?. Clin. Pharmacol. Ther. 77 (2005) 453-454
28. Saeed S.A., Bloch R.M., and Antonacci D.J. Herbal and dietary supplements for treatment of anxiety disorders. Am. Fam. Physician 76 (2007) 549-556
29. Schmidt M., Nahrstedt A., and Lüpke N.P. Piper methysticum (kava) under discussion: observations on quality, effectiveness and safety. Wien Med. Wochenschr. 152 (2002) 382-388
30. Singh Y.N., and Devkota A.K. Aqueous kava extracts do not affect liver function tests in rats. Planta Med. 69 (2003) 496-499
31. Sorrentino L., Capasso A., and Schmidt M. Safety of ethanolic kava extract: results of a study of chronic toxicity in rats. Phytomedicine 13 (2006) 542-549
32. Steiner G.G. The correlation between cancer incidence and kava consumption. Hawaii Med. J. 59 (2000) 420-422
33. Stickel F., Baumüller H.M., Seitz K., Vasilakis D., Seitz G., Seitz H.K., and Schuppan D. Hepatitis induced by Kava (Piper methysticum rhizoma). J. Hepatol. 39 (2003) 62-67
34. Tassaneeyakul W., Birkett D.J., Veronese M.E., McManus M.E., Tukey R.H., Quattrochi L.C., Gelboin H.V., and Miners J.O. Specificity of substrate and inhibitor probes for human cytochromes P450 1A1 and 1A2. J. Pharmacol. Exp. Ther. 265 (1993) 401-407
35. Teschke R., Gaus W., and Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 10 (2003) 440-446
36. Unger M., Holzgrabe U., Jacobsen W., Cummins C., and Benet L.Z. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava-Kava). Planta Med. 68 (2002) 1055-1058
37. Unger M., and Frank A. Simultaneous determination of the inhibitory potency of herbal extracts on the activity of six major cytochrome P450 enzymes using liquid chromatography/mass spectrometry and automated online extraction. Rapid Commun. Mass Spectrom. 18 (2004) 2273-2281
38. van der Watt G., Laugharne J., and Janca A. Complementary and alternative medicine in the treatment of anxiety and depression. Curr. Opin. Psychiatry 21 (2008) 37-42
39. Volz H.P., and Kieser M. Kava-kava extracts WS 1490 versus placebo in anxiety disorders - a randomized placebo-controlled 25-week outpatient trial. Pharmacopsychiatry 30 (1997) 1-5
40. Yueh M.F., Kawahara M., and Raucy J. Cell-based high-throughput bioassays to assess induction and inhibition of CYP1A enzymes. Toxicol. In Vitro 19 (2005) 275-287
41. Zou L., Harkey M.R., and Henderson G.L. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 71 (2002) 1579-1589
42. Zou L., Henderson G.L., Harkey M.R., Sakai Y., and Li A. Effects of kava (Kava-kava, 'Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. Phytomedicine 11 (2004) 285-294